Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established production base for ...
-
-
Recent Updates
- China’s ‘Lipstick King’ confronts slower growth, AI disruption in livestream shopping
- Paper Rex takes down Team Liquid to open VALORANT Champions bid in Shanghai
- Boehringer Ingelheim offloads Shanghai CDMO to local antibody developer
- UCN proposes expanded China fishmeal price assessments covering Peruvian and domestic products
- WorldSkills Team Canada 2026 are Taking on the World in Shanghai
- China Eastern displays services and themed aircraft at WorldSkills Shanghai 2026
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
- US-China Trade War Analysis Amidst Trump-Xi Meeting
- Transformative Opportunity in China’s New Energy Vehicle Sector Explored by Solera and CATARC
- China’s Steel Market Resilience: Analysis and Forecast
Blogroll